Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Crolibulin: Phase I data

Data from 21 patients with unresectable, recurrent or metastatic solid tumors in the open-label, dose-escalation Phase I portion of a U.S. Phase I/II trial showed that

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE